重症肝炎患者HBV与HCV双重感染的血请学调查及其意义探讨

Serological Investigations and Significance of HBV/HCV Double- Infection in the Patients with Severe Hepatitis

采用Ortho抗-HCV C100-3试剂检测了61例重症乙型肝炎,66例轻型慢性乙肝和22例多次受血治疗的非肝脏疾病患者血清中抗HCV C100-3抗体。重症肝炎中,抗-HCV检出率(36.07％)不仅明显高于轻型慢性乙肝组(4.55％),也高于受血治疗组(13.64％);对比分析重症肝炎HBV/HCV双重感染组与单纯HBV感染组的总胆红素、AST/ALT比值及病死率的结果,两组有显著性差异(P<0.05),提示重症肝炎患者由于多次受血治疗及肝脏本身的严重病变,因而对HCV的易感性较高;HBV/HCV双重感染可能加剧了肝脏的损害,加速了肝炎重症化的进程。

Antibody to HCV C100-3 polypeptide (anti-HCV C100-3) was de-termired in the sera of 61 patients with severe hepatitis B (group A), 66 mild chronic hepatitis B (group B) and 22 recipients with multiple blood having a disease other than liver disorders (group C) by Ortho HCV-ELISA diagnostic system. The prevalence of anti-HCV C100-3 was 36.07 % in group A, higher than that (4.55 %) in group B and that (13.64 9%) in group C; the differences of average level of total bilirubin and the ratio of AST/ALT were statistically significant (P<0.05) betwten the group with severe hepatitis of HBV/HCV double-infection and the group with severe hepatitis of single HBV infection. These findings indicate that the patients with sevtre hepatitis may have high susceptibility to HCV, owing to the recipience with blood and/or severe damage of liver tissue ard the HBV/HCV double-infection may accelerate the progression of hepatic necrosis.